Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 15 stocks with the biggest hedge fund momentum, after gaining 25 hedge fund holders during the fourth quarter of 2025. On February 18, Piper Sandler analysts raised their price target on Cogent Biosciences Inc. (NASDAQ:COGT) t0 $52 from $39. According to these analysts, who maintained an Overweight rating on Cogent Biosciences Inc. (NASDAQ:COGT), their $13 increase on the price target is justified by the company’s shift toward regulatory approvals and commercial readiness following fourth-quarter 2025 results.

Piper Sandler noted that Cogent Biosciences Inc. (NASDAQ:COGT) submitted a New Drug Application (NDA) for bezuclastinib in non-advanced systemic mastocytosis, with acceptance expected this month. The drug is positioned for potential approval and launch in the second half of 2026. The company also plans to submit an NDA for second-line gastrointestinal stromal tumors in April and an advanced systemic mastocytosis NDA in the first half of 2026. Given these developments, the company’s focus now turns to execution as it moves toward commercialization, according to the analysts.

Cogent Biosciences Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases.